Change provisions of the Nebraska Medical Cannabis Regulation Act and provide for regulation of medical cannabis
LB677 would substantially revise Nebraska’s medical cannabis framework by creating and expanding the Nebraska Medical Cannabis Regulation Act and related enforcement structure. The bill defines key terms such as cannabis, cannabis products, concentrated cannabis, qualified patient, caregiver, dispensary, cultivator, products manufacturer, testing facility, transporter, and vertical licensee. It sets out a detailed licensing, registration, tracking, packaging, labeling, testing, inspection, and enforcement system for the cultivation, processing, manufacture, transport, sale, and dispensing of medical cannabis in Nebraska.
The bill also establishes the Nebraska Medical Cannabis Commission, housed with the Nebraska Liquor Control Commission, and gives it exclusive authority over licensing and regulation. It creates a Medical Cannabis Control Fund, authorizes fees and civil penalties, and directs tax revenue from medical cannabis sales to the School District Property Tax Relief Credit Fund. In addition, LB677 amends controlled substances and drug paraphernalia provisions so that conduct authorized under the medical cannabis law is not treated as an offense under state controlled substances law, and it updates food, tax, and other statutes to conform to the new medical cannabis regime.
LB677 would have broad effects on Nebraska statutes by carving out medical cannabis from existing controlled-substance restrictions, creating new licensing categories and regulatory powers, and adding special sales and use tax treatment for medical cannabis sales. It would also amend related laws on drug paraphernalia, food regulation, public vehicle markings, and state revenue distribution, while adding detailed rules for packaging, labeling, testing, local zoning, and enforcement. The bill would affect patients, caregivers, cannabis businesses, local governments, the Liquor Control Commission, the Department of Revenue, and other state agencies involved in oversight and taxation.
The bill appears to have faced significant legislative resistance. The voting history shows multiple failed motions on May 20, 2025, including two motions that failed by clear margins and one that passed narrowly, suggesting divided support and ongoing attempts to alter or advance the bill. The final status of the measure was indefinitely postponed, indicating that it did not ultimately move forward. No committee transcript excerpts were provided, so the available record reflects procedural conflict more than substantive committee consensus.
The main points of contention appear to have been the scope of the medical cannabis regulatory system, the creation of a new commission and licensing structure, and the extent to which cannabis should be exempted from existing criminal and regulatory laws. The bill’s detailed provisions on local control, zoning, taxation, packaging, testing, and business ownership requirements likely raised concerns among lawmakers about implementation, public safety, and market structure. The failed motions suggest disagreement over amendments or procedural changes, but the record provided does not identify individual arguments or speakers.